Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christian Nagy

Interventional Cardiology Washington, DC Medical Doctor

NPI 1104981430 CMS profile 186855

2150 Pennsylvania Ave Nw Ste 4-417, Gwmfa - Department Of Cardiology, Washington, DC 20037

Open in the dashboard

General payments

$6,976

120 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christian Nagy of Washington, DC is reported in the CMS Open Payments database as having received $6,976 across 120 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,476 18
2024 General $908 14
2023 General $917 14
2022 General $1,400 22
2021 General $417 15
2020 General $323 15
2019 General $1,535 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christian Nagy
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Christian Nagy were reported at $1,476. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Christian Nagy Interventional Cardiology median Middle half National median
2019 $1,535 $1,097 $329–$3,048 $163
2020 $323 $473 $161–$1,480 $114
2021 $417 $677 $233–$1,827 $132
2022 $1,400 $978 $333–$2,724 $149
2023 $917 $1,136 $382–$2,986 $160
2024 $908 $1,181 $395–$3,326 $164
2025 $1,476 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $3,043 42 payments
  2. Abbott Laboratories $2,849 25 payments
  3. Boston Scientific Corporation $159 8 payments
  4. Medtronic, Inc. $148 8 payments
  5. Cook Medical LLC $143 8 payments
  6. Cardiovascular Systems Inc. $124 7 payments
  7. Abiomed $75 3 payments
  8. AngioDynamics, Inc. $73 3 payments
  9. Recor Medical Inc $46 2 payments
  10. Inari Medical, Inc. $42 1 payment
  11. Other $275 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,218 109 payments
  2. Travel and Lodging $2,757 11 payments
Products named General payments · program years 2019–2025
  1. TRICLIP $1,247 8 payments
  2. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Transcatheter Heart Valves $968 16 payments
  3. Mitra Clip system $860 5 payments
  4. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $741 5 payments
  5. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Transcatheter Heart Valves $604 10 payments
  6. SAPIEN 3 Ultra RESILIA $463 5 payments
  7. MITRACLIP Vascular $269 3 payments
  8. NAVITOR $160 1 payment
  9. MITRACLIP Structural Heart $136 1 payment
  10. MitraClip System $93 1 payment
  11. Other $1,227 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

141

Median for Interventional Cardiology: 2,236

Drug cost

$16,696

Median for Interventional Cardiology: $380,412

Branded share of claims

26.2%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 18 $15,523
Metoprolol Succinate Generic 29 $465
Atorvastatin Calcium Generic 34 $331
Rosuvastatin Calcium Generic 12 $121
Lisinopril Generic 15 $106
Losartan Potassium Generic 14 $93
Clopidogrel Clopidogrel Bisulfate Brand 19 $59

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$44,917

Medicare's payments for the services billed

Medicare patients

118

Average age 76

Services billed

346

52 women, 66 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 70%
Heart failure 50%
Arthritis 50%
Atrial fibrillation 42%
Chronic kidney disease 41%
Diabetes 40%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

120 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record